Mylk3-KO 基因敲除小鼠

1. Phelps, David L, Borley, Jane V, Flower, Kirsty J, Brown, Robert, Ghaem-Maghami, Sadaf. 2017. Methylation of MYLK3 gene promoter region: a biomarker to stratify surgical care in ovarian cancer in a multicentre study. In British journal of cancer, 116, 1287-1293. doi:10.1038/bjc.2017.83. https://pubmed.ncbi.nlm.nih.gov/28350786/

2. Tobita, Takashige, Nomura, Seitaro, Morita, Hiroyuki, Aburatani, Hiroyuki, Komuro, Issei. 2017. Identification of MYLK3 mutations in familial dilated cardiomyopathy. In Scientific reports, 7, 17495. doi:10.1038/s41598-017-17769-1. https://pubmed.ncbi.nlm.nih.gov/29235529/

3. Hajebi Khaniki, Saeedeh, Shokoohi, Farhad, Esmaily, Habibollah, Kerachian, Mohammad Amin. 2023. Analyzing aberrant DNA methylation in colorectal cancer uncovered intangible heterogeneity of gene effects in the survival time of patients. In Scientific reports, 13, 22104. doi:10.1038/s41598-023-47377-1. https://pubmed.ncbi.nlm.nih.gov/38092774/

4. Williams, Jack L, Paudyal, Anju, Awad, Sherine, Cox, Roger D, Metherell, Lou A. 2020. Mylk3 null C57BL/6N mice develop cardiomyopathy, whereas Nnt null C57BL/6J mice do not. In Life science alliance, 3, . doi:10.26508/lsa.201900593. https://pubmed.ncbi.nlm.nih.gov/32213617/